sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements." ;
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved." ;
    dce:title "BEL Framework Large Corpus Document" ;
    pav:authoredBy sub:_5 ;
    pav:version "20131211" .
  sub:_4 prov:value "The c-MET serves as an attractive therapeutic target in SCLC, as shown through small interfering RNA (siRNA) and selective prototype c-MET inhibitor SU11274, inhibiting the phosphorylation of c-MET itself and its downstream molecules such as AKT, S6 kinase, and ERK1/2. The HGF-stimulated phosphorylation of the following downstream phosphokinases was inhibited by SU11274: p-ERK1 [T202/Y204], p-ERK1/2 [T185/Y187], p-MEK1/2 [S221/S225], p38a p-MAP kinase [T180/Y182], p-AKT1 [S473], p-RB [S672], p-adducin-g [S662], and p-CREB [S133]). SU11274 was also effective in abrogating the inhibitory effect of HGF on the specific phosphorylation of p-PKCa [S657], p-PKCa/b [T368], and p-CDK1 [T14/Y15] (Figure 6B)." ;
    prov:wasQuotedFrom pubmed:17667909 .
  sub:_5 rdfs:label "Selventa" .
  sub:assertion prov:hadPrimarySource pubmed:17667909 ;
    prov:wasDerivedFrom beldoc: , sub:_4 .
}